Cybin Announces Closing of $175 Million Registered Direct Offering
TORONTO –(BUSINESS WIRE)–Oct. 31, 2025– Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative
Cybin Announces $175 Million Registered Direct Offering
– Funding of Clinical Stage Programs with Participation from Prominent Biotech Investors – – Use of Proceeds Includes Repayment of High Trail Convertible Note in Full – TORONTO –(BUSINESS WIRE)–Oct. 28, 2025– Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones
– Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company’s deuterated dimethyltryptamine (“DMT”) program for the treatment of Generalized Anxiety Disorder (“GAD”). Topline data expected Q1 2026 – – Continues to advance CYB003, the Company’s proprietary
Cybin to Participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
TORONTO –(BUSINESS WIRE)–Sep. 11, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
– The Phase 2 GAD study has enrolled 36 participants to evaluate the safety and efficacy of CYB004 at 12 weeks after first dose – – Reaffirms top-line data guidance for Q1 2026 – TORONTO –(BUSINESS WIRE)–Sep. 8, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”),
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
TORONTO –(BUSINESS WIRE)–Sep. 4, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today
Cybin to Participate in the Cantor Global Healthcare Conference 2025
TORONTO –(BUSINESS WIRE)–Sep. 3, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today
Cybin Announces Senior Leadership Changes
Doug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated February 10, 2025 , to its short form base shelf prospectus dated August 17,
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
– EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States , Europe and Australia – – Recently cleared to initiate the EMBRACE study in Ireland , Poland , Greece , and the United Kingdom – –
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones – Received European and United Kingdom Medical and Healthcare Products Regulatory Agency (“MHRA”) approval for EMBRACE, the Company’s second pivotal